EGFR-AS1 Promotes Nonsmall Cell Lung Cancer (NSCLC) Progression via Downregulating the miR-524-5p/DRAM1 Axis and Inhibiting Autophagic Lysosomal Degradation
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/4402536
Abstract: Nonsmall cell lung cancer (NSCLC) accounts for the majority of lung cancers. Studies have revealed the regulatory role of lncRNAs in cancer pathogenesis and their potential use as diagnostic and prognostic biomarkers. The epidermal growth… read more here.
Keywords: lung cancer; dram1; mir 524; egfr as1 ... See more keywords
Lowly expressed EGFR-AS1 promotes the progression of preeclampsia by inhibiting the EGFR-JAK/STAT signaling pathway.
Sign Up to like & getrecommendations! Published in 2018 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_201810_16024
Abstract: OBJECTIVE To detect the differentially expressed long non-coding RNA (lncRNA) EGFR-AS1 in the placenta tissues of preeclampsia (PE) patients and normal pregnancies. We also investigated the underlying mechanism of EGFR-AS1 in regulating PE development. PATIENTS… read more here.
Keywords: egfr; egfr as1; htr cells; jak stat ... See more keywords
Overexpression of lncRNA EGFR‑AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non‑small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of oncology"
DOI: 10.3892/ijo.2018.4629
Abstract: Chemoresistance is one of the most important biological elements affecting the progression and prognosis of cancer. Long non‑coding RNAs (lncRNAs) are important regulators and are aberrantly expressed in various types of cancer in humans, including… read more here.
Keywords: poor prognosis; prognosis; egfr as1; cancer ... See more keywords